Zanzalintinib demonstrated antitumor activity in patients with heavily pretreated, advanced clear cell RCC in a phase 1 trial. Zanzalintinib demonstrated antitumor activity in patients with heavily pretreated, advanced clear cell RCC in a phase 1 trial.